NSPR

InspireMDB

Nasdaq / Health Care Equipment & Services

Quote time unavailable

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

20%

Probability

Target price

$1.80

Analysis reference price unavailable

Analysis 2026-09-10 · RankAlpha Sentiment Codex

Most likely

Base case

55%

Probability

Target price

$0.85

Analysis reference price unavailable

Analysis 2026-09-10 · RankAlpha Sentiment Codex

B-

Bear case

25%

Probability

Target price

$0.35

Analysis reference price unavailable

Analysis 2026-09-10 · RankAlpha Sentiment Codex

The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented

AI sentiment snapshot

Latest data as of 2026-09-10

AI commentary

News tone is mixed: the Q2 release highlighted 21% international growth, favorable early clinical outcomes, and a planned cost reset, but the recall caused negative reported U.S. revenue and delayed the U.S. commercial path. No dependable analyst revision or post-print price-reaction evidence is available, and social coverage is absent; confidence therefore remains moderate-low and event-driven.

RankAlpha Sentiment Codex - 2026-09-10

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-09-30catalystRecall-related U.S. disruption remains the near-term overhangHigh impact

Q2 revenue was essentially flat year over year, while recall-related customer credits drove negative reported U.S. revenue and a gross loss. This is the clearest near-term sentiment risk. [#SEC-8K-2026-08-17] [#PR-EARNINGS-2026-08-17]

2026-12-31eventPotential FDA decisions on TCAR and CAS platformsHigh impact

Management said it continues to anticipate FDA decisions later in 2026 for the CGuard Prime 80 cm TCAR implant and the original CGuard platform for traditional carotid stenting. Timing and approval outcomes remain uncertain. [#SEC-8K-2026-08-17] [#EARNINGS-TRANSCRIPT-2026Q2]

2026-12-31catalystInternational demand and early clinical evidence provide operating supportHigh impact

International revenue grew 21% year over year, while CGUARDIANS II reported 100% acute device success in 50 patients and no deaths, strokes, or myocardial infarctions at 30 days. These signals support the product thesis but do not remove regulatory and commercialization risk. [#SEC-8K-2026-08-17]

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-09-10 • Updated nightlySource: Internal modelMethodology